Research & Development

FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Bavarian Nordic's chikungunya virus vaccine candidate, CHIKV VLP, granting it priority review status.

US FDA approves Purdue Pharma’s Zurnai auto-injector

The US Food and Drug Administration (FDA) has approved Purdue Pharma’s new drug application for Zurnai, the first nalmefene hydrochloride auto-injector, designed for the emergency treatment of opioid overdose.

Santen and Cloudbreak enter licence agreement for pterygium treatment

Santen Pharmaceutical has entered into a licensing agreement with Cloudbreak Pharma to develop, manufacture, and commercialise CBT-001, a topical pterygium treatment, for certain territories.

Genmab assumes full ownership of acasunlimab

Genmab has assumed the complete ownership of the acasunlimab development programme, including its continued development and potential commercialisation, contingent on approval.

Vividion Therapeutics to expand capabilities with new R&D centre in US

Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.

Lynch Regenerative Medicine secures funds to develop skin regeneration solutions

Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.

Merck enhances ophthalmology portfolio with EyeBio acquisition

MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.

Juniper to distribute Caris Life Sciences’ molecular profiling services in MEA

Singapore-based Juniper Biologics has secured the distribution rights for Caris Life Sciences' advanced solid tumour molecular profiling services in the Middle East and Africa (MEA).

DoH expands research partnership with Penn Medicine

The Department of Health – Abu Dhabi (DoH) and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) have signed a second Memorandum of Understanding (MoU) to broaden their collaboration in translational research.